Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 2,601–2,700 of 4,628
Gajjala, P. R., Singh, P., Odayar, V., Ediga, H. H., McCormack, F. X., & Madala, S. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032850 · Cited by 8
“limited impact on the survival of patients with IPF [17,18].”
BackgroundJung, S.-W., Heo, S., Oh, Y., Park, K., Park, S., Choi, W., Kim, Y., Jung, S. Y., & Hong, J. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300226 · Cited by 9
Majewski, S., Białas, A. J., Barczyk, A., Batura‐Gabryel, H., Buchczyk, M., Doboszyńska, A., Górska, K., Grabowska-Szkudlarz, L., Jagielska-Len, H., Jarzemska, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144635 · Cited by 9
“6 mL per year in the nintedanib group [6].”
BackgroundMethodResultInfluentialZiritaxestat and Lung Function in Idiopathic Pulmonary Fibrosis
Kawano-Dourado, L. B., Funke-Chambour, M., & Wells, A. U. (2023) · JAMA · doi:10.1001/jama.2023.12637 · Cited by 7
Wu, Y., Zhang, J., Wang, X., Xu, Y., & Zheng, J. (2023) · Acta Histochemica · doi:10.1016/j.acthis.2023.152100 · Cited by 9
Plasma metabolomics and quantitative interstitial abnormalities in ever-smokers
Choi, B., Estépar, R. S. J., Godbole, S. V., Curtis, J. L., Wang, J. M., Estépar, R. S. J., Rosas, I. O., Mayers, J. R., Hobbs, B. D., Hersh, C. P., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02576-2 · Cited by 8
Marcoux, V. S., Lok, S. D., Mondal, P. K., Assayag, D., Fisher, J. H., Shapera, S., Morisset, J., Manganas, H., Fell, C. D., Hambly, N., et al. (2024) · Respirology · doi:10.1111/resp.14695 · Cited by 7
Self-citationWang, S., Yang, G., Zhang, K., Chen, Z., Qiu, M., Hou, S., Zheng, T., Wu, Z., Ma, Q., Zhang, F., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107474 · Cited by 7
Hozumi, H., Miyashita, K., Nakatani, E., Inoue, Y., Yasui, H., Suzuki, Y., Karayama, M., Furuhashi, K., Enomoto, N., Fujisawa, T., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-02922-y · Cited by 10
Self-citationGlenn, L. M., Jackson, D., Barton, C., Lan, D., Fuhrmeister, L., Symons, K., Turnour, L., Tefay, B., Holland, A. E., Goh, N. S. L., et al. (2024) · Respirology · doi:10.1111/resp.14874 · Cited by 7
Mi, Z., Zhou, Y., Yang, X., Zhou, K., & Zhu, X. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1578480 · Cited by 9
Froidure, A., Joannes, A., Mailleux, A., & Crestani, B. (2016) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1171140 · Cited by 7
Abdelhameed, A. S., Nusrat, S., Paliwal, S., et al. (2017) · Preparative Biochemistry & Biotechnology · doi:10.1080/10826068.2016.1275014 · Cited by 7
Lung carcinogenesis and fibrosis taken together: just coincidence?
Giopanou, I., Arendt, K. A. M., & Stathopoulos, G. T. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000390 · Cited by 7
Jones, M. G., Sgalla, G., & Richeldi, L. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201708-1666ed · Cited by 7
Self-citationSpek, C. A., & Duitman, J. (2018) · Journal of Clinical and Translational Research · doi:10.18053/jctres.03.2017s2.004 · Cited by 6
Clinical Trials in IPF: What Are the Best Endpoints?
Spagnolo, P., Cocconcelli, E., & Cottin, V. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_19 · Cited by 9
Self-citationCamuset, J., Naccache, J., Dhalluin, X., et al. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2018.10.618 · Cited by 7
Biomarkers and early treatment of idiopathic pulmonary fibrosis
Kropski, J. A. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30256-5 · Cited by 8
Lai, C., Sbidian, É., Giraudeau, B., & Cleach, L. L. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.09.012 · Cited by 9
The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease
Sarkar, P., Avram, C., & Chaudhuri, N. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1784730 · Cited by 8
Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype
Ananieva, L., Avdeev, S. N., Tyurin, I. E., Lila, A. M., Игоревна, З. А., Maslyanskiy, А. L., Terpigorev, S. A., Stepanyan, I. E., Lashina, E. L., Vasilieva, O. V., et al. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2020-631-636 · Cited by 8
Vozoris, N. T., Wilton, A. S., Austin, P. C., Kendzerska, T., Ryan, C. M., & Gershon, A. S. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01555-x · Cited by 7
Fukihara, J., Maiolo, S., Kovac, J. H., et al. (2022) · Experimental Lung Research · doi:10.1080/01902148.2021.2024301 · Cited by 7
Tanaka, K., Shimoda, M., Sugizaki, T., Ikeda, M., Takafuji, A., Kawahara, M., Yamakawa, N., & Mizushima, T. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00851-7 · Cited by 8
Le‐Deygen, I. M., Safronova, A. S., Mamaeva, P. V., Скуредина, А. А., & Kudryashova, E. V. (2022) · Biophysica · doi:10.3390/biophysica2010008 · Cited by 7
Sakashita, H., Uchibori, K., Jin, Y., Tsutsui, T., Honda, T., Sakakibara, R., Mitsumura, T., Nukui, Y., Shirai, T., Masuo, M., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14376 · Cited by 6
“In attempts to develop a new standardized treatment, the oral intracellular inhibitor nintedanib, a key drug, was shown to slow IPF disease progression in phase III trials.(23) This drug is an anti-fibrotic agent and an antiangiogenesis inhibitor.”
BackgroundWestphalen, S. S., Torres, F. S., Tonetto, M. S., Zampieri, J. F., Torri, G. B., & Garcia, T. S. (2022) · Radiologia Brasileira · doi:10.1590/0100-3984.2021.0033 · Cited by 9
“However, drugs that can delay disease progression and loss of lung function have recently been approved and are also being considered in the treatment of other progressive fibrosing ILDs(3,4).”
BackgroundBicaklioglu, G., Yazır, Y., Duruksu, G., Rençber, S. F., & Yüksel, N. (2022) · International Journal of Ophthalmology · doi:10.18240/ijo.2022.06.08 · Cited by 7
Mikami, S., Miura, Y., Kondo, S., Sakai, K., Nishimura, H., Kyoyama, H., Moriyama, G., Koyama, N., Noguchi, H., Ohkubo, H., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270056 · Cited by 9
“Antifibrotic drugs, nintedanib and pirfenidone, are expected to improve prognosis, and evidence has accumulated regarding their treatment efficacy in patients with interstitial lung diseases; however, in clinical practice, their efficacies vary greatly and adverse events often inhibit their treatment [2, 3].”
BackgroundCheng, S.-L., Sheu, C., Chian, C., Hsu, J., Kao, K., Hang, L., Lin, C., Fang, W., Wang, H., & Perng, D. (2022) · Biomedicines · doi:10.3390/biomedicines10102362 · Cited by 7
Zou, X., Huang, Z., Zhan, Z., Yuan, M., Zhang, Y., Liu, T., Hu, X., Fan, W., Chen, P., Qin, H., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116520 · Cited by 9
Horan, G. S. B., Ye, Y., Adams, M., Parton, A., Cedzik, D., Tang, S., Brown, E. A., Liu, L., Nissel, J., Carayannopoulos, L. N., et al. (2023) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1294 · Cited by 8
Liang, Y., Fan, S., Jiang, Y., Ji, T., Chen, R., Xu, Q., Liu, Y., Xiao, Y., Cai, H., & Dai, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110754 · Cited by 7
Luo, W., Gu, Y., Fu, S., Wang, J., Zhang, J., & Wang, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115762 · Cited by 7
Wu, Y., Li, Q.-Z., Zhao, X., Mu, M., Zou, G.-L., & Zhao, W.-F. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-08101-1 · Cited by 7
Hypoxia-inducible factor 1α modulates interstitial pneumonia-mediated lung cancer progression
Shimoji, K., Nakashima, T., Masuda, T., Namba, M., Sakamoto, S., Yamaguchi, K., Horimasu, Y., Mimae, T., Miyamoto, S., Iwamoto, H., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04756-6 · Cited by 7
Huang, Y., Liu, F., Ren, S., Ding, Y., Chi, M., Huang, W., Gu, W., Qian, H., Yuan, Y., Hou, S., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01764 · Cited by 8
Inherent weaknesses of the current ICD coding system regarding idiopathic pulmonary fibrosis
Tzilas, V., & Bouros, D. E. (2015) · European Respiratory Journal · doi:10.1183/09031936.00205914 · Cited by 9
Insights into idiopathic pulmonary fibrosis in the real world
Cottin, V., & Wuyts, W. A. (2015) · European Respiratory Journal · doi:10.1183/09031936.00036815 · Cited by 8
Self-citationSisson, T. H., & Spagnolo, P. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201512-2319ed · Cited by 7
A global perspective of lung transplantation: Part 1 - Recipient selection and choice of procedure
Girgis, R. E., & Khaghani, A. (2016) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2016.5 · Cited by 7
Interstitial Lung Disease in India. Keep Searching and You’ll Keep Finding
Udwadia, Z. F., & Richeldi, L. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201610-2019ed · Cited by 7
Self-citationIdiopathic Pulmonary Fibrosis and Antifibrotic Treatments: Focus on Experimental Studies
Lunardi, F., Pezzuto, F., Vuljan, S. E., & Calabrese, F. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0080-ra · Cited by 6
Wright, C., Hart, S. P., Allgar, V. L., English, A., Swan, F., Dyson, J., Richardson, G. A., Twiddy, M., Cohen, J., Hussain, J. A., et al. (2019) · ERJ Open Research · doi:10.1183/23120541.00186-2019 · Cited by 8
Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Who to Treat, How to Treat
Kulkarni, T., & Duncan, S. R. (2019) · Current Pulmonology Reports · doi:10.1007/s13665-019-00238-7 · Cited by 8
Progressive Fibrosing Interstitial Lung Disease. A Proposed Integrated Algorithm for Management
Varone, F., Sgalla, G., Iovene, B., & Richeldi, L. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202003-214ps · Cited by 7
Self-citationGender equity in interstitial lung disease
Kawano-Dourado, L. B., Glassberg, M. K., Molina‐Molina, M., Strek, M. E., Wijsenbeek, M. S., & Johannson, K. A. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30310-6 · Cited by 8
Jaśkiewicz, K., Mycroft, K., Maskey‐Warzęchowska, M., Paralusz-Stec, K., Siemiez, N., Nejman‐Gryz, P., Barnaś, M., Krenke, R., & Górska, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082523 · Cited by 9
“Nintedanib, which, among others, exhibits antiVEGF activity, is currently one of the two compounds approved for IPF treatment with an explicitly documented antifibrotic effect [41].”
BackgroundDynamics in diagnoses and pharmacotherapy before and after diagnosing idiopathic pulmonary fibrosis
Davidsen, J. R., Lund, L. C., Laursen, C. B., Hallas, J., & Henriksen, D. P. (2020) · ERJ Open Research · doi:10.1183/23120541.00479-2020 · Cited by 7
“Except for two highly targeted antifibrotic drugs, pirfenidone and nintedanib, no pharmacological treatment has proven effective to IPF [2, 4, 5].”
BackgroundEldersveld, J. M., Yi, E. S., Kunze, K. L., Smith, M. L., Tazelaar, H. D., & Larsen, B. T. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0100-oa · Cited by 7
Chang, W., Chen, C.-M., Sheu, C., Liao, S., Hsu, Y., Tsai, M., & Kuo, P. (2020) · Molecules · doi:10.3390/molecules25225458 · Cited by 10
Aronson, K. I., Ali, M., Reshetynak, E., Kaner, R. J., Martínez, F. J., Safford, M. M., & Pinheiro, L. C. (2021) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-020-00282-x · Cited by 10
Wells, A. U. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00173-9 · Cited by 7
Molecular Markers and the Promise of Precision Medicine for Interstitial Lung Disease
Newton, C. A., & Herzog, E. L. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.011 · Cited by 7
Bai, Y., Zhang, Y., Chu, P., Wang, C., Li, L., Qi, Y., Han, X., Zhang, B., Sun, H., Li, Y., et al. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128238 · Cited by 9
Gundogan, B. D., Taskinlar, S., Arikoglu, T., Balcı, Y., & Citak, E. C. (2021) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002266 · Cited by 7
Kang, M., Veeraraghavan, S., Martin, G. S., & Kempker, J. A. (2021) · ERJ Open Research · doi:10.1183/23120541.00142-2021 · Cited by 9
Deficiency of CARMA3 attenuates the development of bleomycin induced pulmonary fibrosis
Wu, Y., Qi, Y., Qiu, Z., & Chen, W. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.10.013 · Cited by 8
Bassi, I., Hollis, G., Cottin, V., Harari, S. A., Zwanenburg, E., Veltkamp, M., Casanova, Á., Fletcher, M. J., Masefield, S. C., Powell, P., et al. (2016) · ERJ Open Research · doi:10.1183/23120541.00102-2015 · Cited by 8
Self-citationDelayed Presentation of Hepatocellular Liver Injury After Nintedanib Administration
Olin, J. L., Woods, J. A., & Garner, S. J. (2016) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000464 · Cited by 7
Trends in diagnosis and management of idiopathic pulmonary fibrosis in Canada
Weatherald, J. C., McFadden, R. G., & Fell, C. D. (2017) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2017.1314778 · Cited by 8
Recommendations for evaluating and managing idiopathic pulmonary fibrosis
Provencher, D. M., & Jauregui, A. R. (2018) · JAAPA · doi:10.1097/01.jaa.0000544299.00459.a4 · Cited by 7
Naftopidil reduced the proliferation of lung fibroblasts and bleomycin‐induced lung fibrosis in mice
Urushiyama, H., Terasaki, Y., Nagasaka, S., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14255 · Cited by 7
Outcome of lung transplantation in non‐idiopathic pulmonary fibrosis interstitial lung disease
Bode, H., Verleden, S. E., Wuyts, W. A., Yserbyt, J., Verleden, G. M., & Vos, R. (2019) · Clinical Transplantation · doi:10.1111/ctr.13661 · Cited by 8
Older Idiopathic Pulmonary Fibrosis Male Patients Are at a Higher Risk of Nintedanib Dose Reduction
Harari, S. A., Specchia, C., Lipsi, R., Cassandro, R., & Caminati, A. (2020) · Respiration · doi:10.1159/000508667 · Cited by 8
Wound dehiscence with nintedanib after cardiac surgery: A cautionary tale
He, C., & Raman, J. (2020) · JTCVS Techniques · doi:10.1016/j.xjtc.2020.10.036 · Cited by 7
Combined Pulmonary Fibrosis and Emphysema, a clinical review
Tzilas, V., & Bouros, D. E. (2016) · COPD Research and Practice · doi:10.1186/s40749-016-0018-1 · Cited by 7
Ziehr, D. R., Li, F., Parnell, K. M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.25.591150 · Cited by 7
Song, L., Zhou, H., Ye, P., Li, Q., Chen, K., Zhang, Y., Zhao, F., Shi, J., Luo, Y., Zhu, M., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13654 · Cited by 6
Cheung, D., Fong, A., Ding, H. T., Cabanski, C. R., Wang, J., Chen, Y., Bush, J., Harris, J. M., & Pan, L. (2021) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2021.102051 · Cited by 6
Sutherland, L., & Carter, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32597 · Cited by 8
“In an exemplar case, the multi-kinase inhibitor nintedanib has been developed for both idiopathic pulmonary fibrosis and NSCLC: the former dose being selected based on a randomised dose-ranging phase 2 trial [120], whereas the higher oncology dose was selected based the MTD alone [121].”
BackgroundFujimoto, S., Katsurada, N., Hazama, D., et al. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3932-24 · Cited by 6
The interstitial lung disease patient pathway: from referral to diagnosis
Lough, G., Abdulqawi, R., Amanda, G., Antoniou, K., Azuma, A., Baldi, M. M., Bayoumy, A., Behr, J., Bendstrup, E. M., Bouros, D. E., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00899-2024 · Cited by 7
Self-citationQiu, Y., Zhu, J., Chopra, P., Elpers, B., Dieyi, C., Byrne, C., Tang, J., Ye, W., Govindaraj, K., & Fischer, A. (2024) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241280704 · Cited by 7
Miranda, S. M. D., Paiva, S. D. P. C., Pereira, L. F. F., et al. (2024) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2024.103106 · Cited by 6
Live-cell imaging of human liver fibrosis using hepatic micro-organoids
Guan, Y., Fang, Z., Hu, A., Roberts, S., Wang, M., Ren, W., Johansson, P. K., Heilshorn, S. C., Enejder, A., & Peltz, G. (2025) · JCI Insight · doi:10.1172/jci.insight.187099 · Cited by 6
Ravichandran, P., Canizela, C. C., Sayed, A., & Hussain, R. M. (2024) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000551 · Cited by 6
Identification of a Potent CDK8 Inhibitor Using Structure-Based Virtual Screening
Lin, T. E., Chou, C.-H., Wu, Y., Sung, T.-Y., Hsu, J., Yen, S., Hsieh, J., Chang, Y.-W., Pan, S., Huang, W., et al. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c02011 · Cited by 6
Xing, X., Yan, X.-Y., Tan, Y.-W., Liu, Y., Cui, Y.-X., Feng, C.-L., Cai, Y.-R., Dai, H.-L., Gao, W. Y., Zhou, P., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.02.028 · Cited by 8
Cocconcelli, E., Bernardinello, N., Cameli, P., Liberti, R., Alhamad, E. H., Gregori, D., Pianigiani, T., Dartora, C., Messina, R., Leo, I. D., et al. (2025) · Lung · doi:10.1007/s00408-025-00789-4 · Cited by 11
He, J., Yue, H., Zhang, S., Dong, R., Zhang, F., Wang, X., Wang, K., Zhang, H., Yang, D., Dong, Z., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03218-5 · Cited by 6
The use of mechanical ventilation in interstitial lung disease
Nolan, T., Dwyer, I., & Geoghegan, P. (2025) · Breathe · doi:10.1183/20734735.0172-2024 · Cited by 9
Wang, T., Cui, Z., Ou, Y., Lou, S., Chen, H., Zhu, C., Zhou, L., & Zou, F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1530697 · Cited by 17
Treatable traits in interstitial lung disease: a narrative review
Harrison, M., Lawler, C., Lake, F., Navaratnam, V. V., Fermoyle, C. C., Moodley, Y. P., & Corte, T. J. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251335774 · Cited by 8
Takuma, S., Hozumi, H., Miyashita, K., Inoue, Y., Yasui, H., Suzuki, Y., Karayama, M., Furuhashi, K., Enomoto, N., Fujisawa, T., et al. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108185 · Cited by 6
Self-citationAlamandine reduces oxidative stress and preserves the epithelium in BLM-induced pulmonary fibrosis
Blanco, A., Fernandes, R., Guimarães, G. R., & Rigatto, K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177995 · Cited by 6
Mangiferin Against Respiratory Diseases: Pharmacological Targets and Prospects
Ahmed, K. A., Afrin, N., Ghosh, P., Heya, I. A., Akash, S. R., Moni, A., Islam, M. N., Hossain, M. G., Sinopoli, A., Hannan, M. A., et al. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70163 · Cited by 7
Lalla, F., Latella, A., Varone, F., Iovene, B., Richeldi, L., & Sgalla, G. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03916-2 · Cited by 12
Self-citationAssayag, D., Adegunsoye, A., Khor, Y. H., Bonella, F., Borie, R., Buendía-Roldán, I., Chaudhuri, N., Gibson, K. F., Johannson, K. A., Kaminski, N., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202509-2336st · Cited by 7
Self-citationCancer-associated fibroblasts in non-small cell lung cancer therapy: Challenges and opportunities
Deng, S., Li, Y., Peng, L., Li, J., & Zhang, L. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189568 · Cited by 7
Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use
Diamantopoulos, A., Maher, T. M., Schoof, N., Esser, D., & LeReun, C. (2018) · PharmacoEconomics - Open · doi:10.1007/s41669-018-0085-0 · Cited by 6
“Nintedanib was shown to inhibit fibroblast proliferation, migration, contraction and differentiation to the active extracellular matrix-secreting myofibroblast [9, 10].”
InfluentialNOVEL NANOPARTICULATE SYSTEMS FOR IDIOPATHIC PULMONARY FIBROSIS: A REVIEW
Dudhat, K. R., & Patel, H. V. (2020) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2020.v13i11.39035 · Cited by 8
Jia, J., Yang, L., Zhong, X., & He, L. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210322103340 · Cited by 6
Role of cancer-associated fibroblasts in tumor microenvironment
Mir, M. A., Sofi, S., & Aisha, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-443-18696-7.00002-6 · Cited by 6
Hu, Y., Li, L., Tian, Y., Xiao, Y., Tang, J., Zeng, S., Zou, Z., & Shang, H. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116029 · Cited by 7
An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis
Ford, P., Kreuter, M., Brown, K. K., Wuyts, W. A., Wijsenbeek, M. S., Israël‐Biet, D., Hubbard, R., Nathan, S. D., Nunès, H., Penninckx, B., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00636-2023 · Cited by 10
Self-citationCueto‐Robledo, G., Tovar-Benitez, D., Alfaro, A., & González-Hermosillo, L.-M. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102404 · Cited by 6
Wang, Y., Xue, F., Cheng, W., Zhao, Q., Song, N., Shi, Z., Liu, H., Li, Y., Tang, Q., Liu, Q., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00067 · Cited by 6
Pulmonary Manifestations of Sjögren's Disease
Byrne, L., McCarthy, C., Fabre, A., & Gupta, N. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1785675 · Cited by 9
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.